Atyr Pharma Inc (NASDAQ: ATYR) is -0.55% lower on its value in year-to-date trading and has touched a low of $1.42 and a high of $4.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATYR stock was last observed hovering at around $3.34 in the last trading session, with the day’s gains setting it 0.26%.
Currently trading at $3.60, the stock is 14.25% and 7.19% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.38 million and changing 7.78% at the moment leaves the stock 23.54% off its SMA200. ATYR registered 129.30% gain for a year compared to 6-month loss of 8.43%. The firm has a 50-day simple moving average (SMA 50) of $3.3585 and a 200-day simple moving average (SMA200) of $2.91415.
The stock witnessed a 21.62% gain in the last 1 month and extending the period to 3 months gives it a -6.74%, and is 7.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.64% over the week and 9.49% over the month.
Atyr Pharma Inc (ATYR) has around 59 employees, a market worth around $319.90M and $0.23M in sales. Profit margin for the company is -27243.83%. Distance from 52-week low is 153.52% and -22.75% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.03%).
The EPS is expected to grow by 17.86% this year.
Atyr Pharma Inc (ATYR) Top Institutional Holders
92.0 institutions hold shares in Atyr Pharma Inc (ATYR), with institutional investors hold 63.48% of the company’s shares. The shares outstanding are 88.86M, and float is at 86.00M with Short Float at 11.66%. Institutions hold 62.06% of the Float.
Atyr Pharma Inc (ATYR) Insider Activity
The most recent transaction is an insider purchase by Gross Jane A, the company’s Director. SEC filings show that Gross Jane A bought 3,750 shares of the company’s common stock on Mar 17 ’25 at a price of $4.00 per share for a total of $15000.0. Following the purchase, the insider now owns 9750.0 shares.
Atyr Pharma Inc disclosed in a document filed with the SEC on Feb 04 ’25 that Broadfoot Jill Marie (Chief Financial Officer) sold a total of 1,254 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $3.78 per share for $4740.0. Following the transaction, the insider now directly holds 31763.0 shares of the ATYR stock.
Still, SEC filings show that on Feb 04 ’25, DENYES NANCY (General Counsel) disposed off 899 shares at an average price of $3.78 for $3398.0. The insider now directly holds 26,555 shares of Atyr Pharma Inc (ATYR).
